A new treatment for hip osteoarthritis: clinical evidence for the efficacy of autologous conditioned serum

Abstract

The purpose of the present study was to investigate the effect of intra-articular injections of autologous conditioned serum on human hip osteoarthritis and to test whether a potential treatment effect might be increased by additional injections of steroids and the recombinant interleukin-1 receptor antagonist protein anakinra. We compared the effects of autologous conditioned serum 46 hip osteoarthritis patients), autologous conditioned serum+cortisone (56 patients), and autologous conditioned serum+cortisone+recombinant interleukin-1 receptor antagonist protein (17 patients) in a retrospective clinical study by means of the Visual Analogue Scale for pain (pre- vs posttreatment). Over 14 months, treatment resulted in a large, statistically significant improvement for patients in all three groups, independent of the severity of osteoarthritis. Neither cortisone nor cortisone+recombinant interleukin-1 receptor antagonist protein increased the beneficial treatment effect over and above the effect of autologous conditioned serum alone. Autologous conditioned serum successfully reduces pain in hip osteoarthritis. In severe hip osteoarthritis, the sole application of autologous conditioned serum can be even more beneficial than the combination of autologous conditioned serum with steroids.

scAAVIL-1ra dosing trial in a large animal model and validation of long-term expression with repeat administration for osteoarthritis therapy

“…12 There continues to be mounting clinical evidence that proves efficacy of products containing high levels of IL-1ra especially in the high motion joints that have the highest occurrence of OA such as the hip and the knee. 9,10,18 …”

An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease

“…The neutralization of the pro-inflammatory cytokine IL-1β by the use of receptor antagonist proteins (IRAPs) such as the autologous conditioned serum marketed under the trade name Orthokine injected intraarticularly was tested in patients with knee and hip OA in preliminary studies with beneficial response (118)(119)(120). Orthokine, regardless the concomitant use of steroids and anakinra, administered by IA injection in hip OA showed to improve clinical signs and symptoms (120).…”

“…Orthokine, regardless the concomitant use of steroids and anakinra, administered by IA injection in hip OA showed to improve clinical signs and symptoms (120). In contrast, a single IA injection of anakinra was not associated with improvements in OA symptoms compared with placebo in patient with knee OA (59).…”

The efficacy and safety of autologous conditioned serum (ACS) injections compared with betamethasone and placebo injections in the treatment of chronic shoulder joint pain due to supraspinatus tendinopathy: a prospective, randomized, double-blind, controlled study

“…The cell-free supernatant, which contains these cytokines, is then extracted from the coagulated blood using centrifugation and re-injected into the affected tissue through a sterile filter. ACS has shown efficacy for treatment of knee and hip osteoarthritis (OA) in randomized controlled trials [12][13][14], as well as lumbar radicular compression [15] and muscular injuries [16].…”